CM
BPMC

Crestline Management’s Blueprint Medicines BPMC Stock Holding History

Crestline Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-26,979
Closed -$1.71M – 160
2018
Q2 		$1.71M Buy
+26,979
New +$2.15M 0.18% 160

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Crestline Management's BPMC Position: Q3 2018 in Review

Crestline Management sold out of Blueprint Medicines (BPMC) in Q3 2018, closing a stake of 26,979 shares — an estimated $1.71M sold.

Crestline Management first reported a position in BPMC in Q2 2018 and held it in 1 quarter. The position peaked at $1.71M in Q2 2018. 188 funds tracked by Wall St. Rank hold BPMC as of Q3 2018.

  • Crestline Management reported no remaining Blueprint Medicines position as of Q3 2018 after selling out during the quarter.
  • Crestline Management sold 26,979 Blueprint Medicines shares in Q3 2018, an estimated $1.71M.
  • Crestline Management first reported a position in Blueprint Medicines in Q2 2018 and held it in 1 quarter.
  • Crestline Management's Blueprint Medicines position peaked at $1.71M in Q2 2018.
  • 188 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2018.

Based on Crestline Management's 13F filing for Q3 2018, filed 14 Nov 2018.